Padagis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Padagis (US): 30 reconciled FDA prescription therapies, $110.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies30
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$110.5M
2024 Medicare Part D Spend$38.4M
2024 Medicaid Spend$72.1M
California HCAI SB 17 Filings1 WAC filings (max 36.1% 2-yr change)